Merck & Co and SR One were among the investors in a series C round for the small molecule drug developer led by Pivotal BioVenture Partners.
US-based small molecule drug developer HotSpot Therapeutics completed a $100m series C round on Monday led by Pivotal BioVenture Partners, a life sciences investment vehicle owned by property developer Nan Fung.
The round included pharmaceutical firm Merck & Co’s MRL Ventures Fund and SR One Capital Management, the investment firm spun off by pharmaceutical firm GlaxoSmithKline, as well as B Capital Group, the investment partner of consulting firm Boston Consulting Group.
Caas Capital Management, Revelation Partners, Pavilion Capital, Monashee Investment…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
